<DOC>
	<DOCNO>NCT02290041</DOCNO>
	<brief_summary>Clinical trial phase I/II , test concept , blind double , control placebo , randomize 2:1 ( Treatment : placebo ) , total 15 patient include</brief_summary>
	<brief_title>Treatment With MSC HIV-infected Patients With Controlled Viremia Immunological Discordant Response</brief_title>
	<detailed_description>Clinical trial phase I/II , test concept , blind double , control placebo , randomize , total 15 patient include In initial phase , include 5 patient sequential form , minimum 15 day safety period first infusion patient first one follow patient . These first 5 patient randomize , treat medicine investigation . When last one 5 patient receive first three foreseen dos , safety information evaluate Independent Data Monitoring Committee . If evaluation positive , continued trial recruit rest patient ( n = 10 ) . After randomization , 5 patient receive cellular therapy 5 receive infusion placebo product .</detailed_description>
	<mesh_term>Viremia</mesh_term>
	<criteria>Age &gt; 18 year . Both sex In antiretroviral therapy HIV Infection HIV Viral load &lt; 50 copy / ml &gt; 1 year Value CD4 + &lt; 350/mcl Immunological discordant response define increase &lt; 75 &lt; 150 CD4+ cell count one two year undetectable viraemia , respectively , regard basal determination recount CD4 + &lt; 350/mcl 3 year antiretroviral treatment undetectable viraemia ( &lt; 50 copies/ml ) â‰¥ 1 year Writing inform consent Commitment utilization contraceptive method prove efficiency men woman duration clinical trial Pregnancy , lactation , denial use contraceptive method prove efficiency men woman Opportunistic infection ongoing treatment Hepatitis B virus/hepatitis C virus coinfection Hepatic cirrhosis stadium C Child Pugh 's classification aetiology Portal hypertension / hypersplenism aetiology Presence malignant neoplasia Treatment steroid , immunomodulator , interferon , chemotherapy medicinal product could reverberate number CD4 last twelve month Any analytical alteration 3 4 grade ( AIDS Clinical Trials Group scale ) , confirm , analytical prior first infusion</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2014</verification_date>
	<keyword>mesenchymal stem cell</keyword>
	<keyword>Virus human immunodeficiency Infection</keyword>
</DOC>